National Multiple Sclerosis Society

News and Video Search Results

News coverage

Global Digital Biomarkers Market Trends and Forecasts to 2035: Leading Players are AliveCor, BACtrack, Biogen, BioSensics, Empatica, Eyenuk, Feel Therapeutics, Icometrix, and Quibim

GlobeNewswire 10 May 2024

Dublin, May 10, 2024 (GLOBE NEWSWIRE) -- The "Digital Biomarkers Market: Industry Trends and Global Forecasts, till 2035:..

ORYZON to Provide Corporate Progress Updates at Several Events in May
GlobeNewswire 09 May 2024
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
GlobeNewswire 08 May 2024
Apheresis Market to Surpass Valuation of USD 6,882.1 Billion By 2032: Astute Analytica
GlobeNewswire 06 May 2024
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
GlobeNewswire 18 Apr 2024

0 shares 1 views

You might like

National Multiple Sclerosis Society media coverage

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

GlobeNewswire 17 Apr 2024

· Continuous Kesimpta^® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years)..

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
GlobeNewswire 12 Mar 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire 08 Mar 2024
Partnership Is Key to Caring for Multiple Sclerosis Patients Throughout Their Journey
Accesswire 07 Mar 2024
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
GlobeNewswire 01 Mar 2024

Advertisement

More coverage

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

GlobeNewswire 28 Feb 2024

Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectivelyConference..

MS Society forces 90-year-old volunteer to step down for misunderstanding trans pronouns
Christian Post 19 Feb 2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
GlobeNewswire 01 Feb 2024
Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders: 2022-23 Data, Forecasts for 2024- 2026 and CAGR Projections through 2028
GlobeNewswire 22 Dec 2023
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
GlobeNewswire 14 Dec 2023